CC
NBSE

Cannell & Co’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Cannell & Co’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,230
Closed -$915K – 263
2017
Q4 		$915K Buy
1,230
+498
+68% +$192K 0.03% 173
2017
Q3 		$211K Hold
732
– – 0.01% 232
2017
Q2 		$187K Buy
+732
New +$197K 0.01% 236

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Cannell & Co's NBSE Position: Q1 2018 in Review

Cannell & Co sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2018, closing a stake of 1,230 shares — an estimated $915K sold.

Cannell & Co first reported a position in NBSE in Q2 2017 and held it in 3 quarters. The position peaked at $915K in Q4 2017. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2018.

  • Cannell & Co reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Cannell & Co sold 1,230 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $915K.
  • Cannell & Co first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Cannell & Co's NeuBase Therapeutics, Inc. Common Stock position peaked at $915K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Cannell & Co's 13F filing for Q1 2018, filed 9 May 2018.